Buy Gilead Sciences (GILD) Stock at 52-Week Highs?

Core Insights - Gilead Sciences has reached new 52-week highs, joining other healthcare stocks amid broader market pullbacks [1][2] - The stock has increased nearly 30% year-to-date, while the broader market indexes are in negative territory [2] Gilead's Industry Leadership - Gilead is a leader in developing drugs for HIV treatment and has a diverse portfolio for liver diseases, inflammation, respiratory diseases, and hematology/oncology [3] - Expected revenue for 2024 is $28.75 billion, with a projected dip of 1$29.7 billion in fiscal 2026 [3] Gilead's EPS Growth - Annual earnings are projected to increase by 70% in FY25 to $7.87 per share, up from$4.62 last year, with a further 5% increase expected in FY26 [4] Gilead's P/E Valuation - Gilead trades at a forward earnings multiple of 14.6X, below Johnson & Johnson's 15.6X and the industry average of 19.1X [8] Gilead's Dividend - Gilead offers a 2.65% annual dividend yield, surpassing the S&P 500 average of 1.27% and the industry average of 1.49% [10] Bottom Line - Gilead Sciences holds a Zacks Rank 2 (Buy), indicating potential for further upside as EPS estimates for FY25 and FY26 have trended higher [12]